Ruthenium brachytherapie and sandwich therapy for medium sized uveal melanomas

• Published in: Acta ophthalmologica (Oxford, England) England), 2024-01, Vol.102 (S279), p.n/a
• Main Authors: Do, Ha‐Vy, Czapla, Celine, Vogel, Heike, Hildebrandt, Guido, Guthoff, Rudolf, Fuchsluger, Thomas, Brockmann, Claudia
• Format: Article
• Language: English
• Subjects: Acuity; Brachytherapy; Melanoma; Metastases; Patients; Radiation therapy; Retinopathy; Side effects; Thermotherapy; Tumors; Visual acuity
• ISSN: 1755-375X; 1755-3768
• DOI: 10.1111/aos.15978

Aims/Purpose: Brachytherapy using ruthenium is an established procedure for the treatment of uveal melanomas, the most common malignant primary intraocular tumour in adults. The supplementary use of transpupillary thermotherapy (TTT) with brachytherapy is known as sandwich therapy. Due to the rarity of uveal melanomas, long‐term outcome of large cohorts treated by ruthenium brachytherapy with and without TTT is of special clinical and scientific interest. Methods: Based on a retrospective longitudinal study, patients with uveal melanoma who received treatment using ruthenium brachytherapy at the Department of Ophthalmology from 1994 to 2021, were analysed. The evaluation includes tumour height, visual acuity, radiation data, side effects, local recurrence, bulbus preservation and occurrence of metastasis. Results: Overall, 150 patients with medium sized uveal melanoma (tumour height >3.0 and ≤7.0 mm) who received ruthenium brachytherapy were included. The mean age of patients at diagnosis was 63.5 ± 12.9 years (median 65), the proportion of women was 60.0%. Tumours were located centrally in 48.7% of cases; ciliary body involvement was seen in 4%. Additive transpupillary thermotherapy (TTT) was performed in 70.7% of cases as part of a sandwich therapy. After therapy and a mean follow‐up of 68.0 ± 58.3 years tumours height was significantly reduced from 4.5 ± 1.1 to 1.4 ± 1.6 mm (p